Vorasidenib has been approved by the U.S. Food and Drug Administration (FDA) for patients with Grade 2 gliomas with IDH1 or IDH2 mutations. Based on evidence from the INDIGO clinical trial, a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback